DaVita (DVA)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$183.99+1.28%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · DVA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks DVA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to deliver adjusted operating income within or above guidance ranges through disciplined execution and operational rigor.
Stated as a priority in 6 of last 6 quarters. Operating income increased from $439 million in 2025-Q1 to $579 million in 2026-Q2. Management has consistently emphasized delivering operating income within guidance, which for 2026 is $2.15-$2.25 billion. The trajectory shows delivering against this priority with steady growth and reaffirmed guidance.
“We maintain our strategic focus on exciting new innovations... Operating income was $579 million.”
“Operating income was $482 million. We have consistently delivered... strong financial performance.”
“Operating income was $561 million. We are confident in our ability to continue to deliver clinically and financially.”
“Operating income was $506 million and adjusted operating income was $517 million. On track to achieve full-year guidance.”
“Operating income was $538 million and adjusted operating income was $551 million. Delivered on financial commitments.”
“Operating income was $439 million. Strong first quarter performance demonstrates stability and consistency.”
Maintain disciplined cash flow generation to meet or exceed free cash flow guidance targets.
Stated as a priority in 6 of last 6 quarters. Free cash flow improved from negative $45 million in 2025-Q1 to $256 million in 2026-Q2. Management's 2026 guidance targets free cash flow between $1.0 billion and $1.25 billion. The trajectory shows progress with improving cash flow generation supporting the guidance.
“Free cash flow was $256 million. Current 2026 guidance is $1,000 to $1,250 million.”
Continue to repurchase shares under the authorized buyback program to return capital to shareholders.
Stated as a priority in 6 of last 6 quarters. The company repurchased shares each quarter, including 2.2 million shares in 2026-Q2 at an average price of $154.95. This consistent execution demonstrates ongoing commitment to the share repurchase program.
“Repurchased 2.2 million shares at an average price of $154.95 per share.”
Grow the number of patients in risk-based integrated kidney care arrangements to enhance value-based care.
Stated as a priority in 6 of last 6 quarters. The integrated kidney care patient base increased from approximately 62,100 in 2025-Q1 to 64,900 in 2026-Q2. This reflects steady growth aligned with management's stated focus on value-based care expansion.
“Approximately 64,900 patients in risk-based integrated care arrangements.”
DaVita aims to maintain its operating income guidance for the fiscal year 2026.
Over the trailing year it converted 0.84x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Free cash flow was $140 million. We have consistently delivered strong financial performance.”
“Free cash flow was $309 million. Confident in ability to deliver free cash flow guidance.”
“Free cash flow was $604 million. On track to achieve full-year guidance.”
“Free cash flow was $157 million. Delivered on financial commitments with disciplined execution.”
“Free cash flow was negative $45 million. Strong first quarter performance.”
“Repurchased 3.0 million shares at an average price of $133.70 per share.”
“Repurchased 2.7 million shares at an average price of $122.78 per share.”
“Repurchased 3.3 million shares at an average price of $140.67 per share.”
“Repurchased 3.1 million shares at an average price of $144.00 per share.”
“Repurchased 3.7 million shares at an average price of $148.94 per share.”
“Approximately 62,600 patients in risk-based integrated care arrangements.”
“Approximately 66,000 patients in risk-based integrated care arrangements.”
“Approximately 64,900 patients in risk-based integrated care arrangements.”
“Approximately 64,400 patients in risk-based integrated care arrangements.”
“Approximately 62,100 patients in risk-based integrated care arrangements.”